Senseonics Holdings, Inc. (SENS) News
Filter SENS News Items
SENS News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
SENS News Highlights
-
404 Page not found Error: Page not found
The requested URL was not found on this server.
-
404 Page not found Error: Page not found
The requested URL was not found on this server.
-
404 Page not found Error: Page not found
The requested URL was not found on this server.
Latest SENS News From Around the Web
Below are the latest news stories about SENSEONICS HOLDINGS INC that investors may wish to consider to help them evaluate SENS as an investment opportunity.
Senseonics Holdings sees Q4 revenue of ~$8.3MMore on Senseonics |
Senseonics Stock Surges 42% After Hours on Preliminary Revenue ReportOver 1,000 U.S. prescribers adopted Eversense 365 in 2024. |
Senseonics Holdings, Inc. Announces Business Updates Including Preliminary 2024 Results, 365 Launch Update and Cancellation of Special MeetingGERMANTOWN, Md., Jan. 08, 2025 (GLOBE NEWSWIRE) -- Senseonics Holdings, Inc. (NYSE American: SENS), a medical technology company focused on the development and manufacturing of long-term, implantable continuous glucose monitoring (CGM) systems for people with diabetes, today announced operational, financial and other business updates. Recent Highlights & Accomplishments Generated preliminary unaudited fourth quarter revenue of approximately $8.3 million, and preliminary unaudited full year 2024 |
Here’s Why Senseonics Holdings, Inc. (NYSE:SENS) Is Among the Best Diabetes Stocks to Buy Under $10We recently compiled a list of the 10 Best Diabetes Stocks To Buy Under $10. In this article, we are going to take a look at where Senseonics Holdings, Inc. (NYSE:SENS) stands against the other diabetes stocks. Global Growth and Innovation in Diabetes Care: The Rise of Continuous Glucose Monitors and AI Integration About 422 million […] |
Senseonics Holdings, Inc. Provides Update on Eversense 365 LaunchStrong Eversense® 365 early launch indicators illustrated by largest number of new patient shipments and largest number of prescribing providers in any month under Ascensia partnershipGERMANTOWN, Md., Dec. 09, 2024 (GLOBE NEWSWIRE) -- Senseonics Holdings, Inc. (NYSE American: SENS), a medical technology company focused on the development and manufacturing of long-term, implantable continuous glucose monitoring (CGM) systems for people with diabetes, today provided commercial updates related to t |
Senseonics Holdings, Inc. to Participate in Upcoming Investor ConferencesGERMANTOWN, Md., Nov. 12, 2024 (GLOBE NEWSWIRE) -- Senseonics Holdings, Inc. (NYSE American: SENS), a medical technology company focused on the development and manufacturing of long-term, implantable continuous glucose monitoring (CGM) systems for people with diabetes, today announced that management will participate in the following investor conferences in November: Stifel 2024 Healthcare ConferenceFormat: Corporate overview and one-on-one meetingsDate: Tuesday, November 19, 2024Time: 9:10 am E |
Senseonics Holdings Inc (SENS) Q3 2024 Earnings Call Highlights: Navigating Revenue Challenges ...Despite a dip in quarterly revenue, Senseonics Holdings Inc (SENS) celebrates FDA approval of its groundbreaking Eversense 365 glucose monitor, setting the stage for future growth. |
Senseonics Holdings (SENS) Reports Q3 Loss, Tops Revenue EstimatesSenseonics (SENS) delivered earnings and revenue surprises of -33.33% and 5.99%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock? |
Senseonics: Q3 Earnings SnapshotGERMANTOWN, Md. AP) — Senseonics Holdings Inc. SENS) on Thursday reported a loss of $24 million in its third quarter. |
Senseonics Holdings, Inc. Reports Third Quarter 2024 Financial ResultsGERMANTOWN, Md., Nov. 07, 2024 (GLOBE NEWSWIRE) -- Senseonics Holdings, Inc. (NYSE American: SENS), a medical technology company focused on the development and manufacturing of long-term, implantable continuous glucose monitoring (CGM) systems for people with diabetes, today reported financial results for the third quarter ended September 30, 2024. Recent Highlights & Accomplishments: Eversense® 365 approved in the US as an integrated continuous glucose monitoring (iCGM) system for people with T |